Search Results - "Köhm, M"

Metabolomic and lipidomic fingerprints in inflammatory skin diseases – Systemic illumination of atopic dermatitis, hidradenitis suppurativa and plaque psoriasis by Rischke, S., Schäfer, S.M.G., König, A., Ickelsheimer, T., Köhm, M., Hahnefeld, L., Zaliani, A., Scholich, K., Pinter, A., Geisslinger, G., Behrens, F., Gurke, R.

“…Auto-inflammatory skin diseases place considerable symptomatic and emotional burden on the affected and put pressure on healthcare expenditures. Although most…”
Get full text

Increased Serum Levels of the IL‐33 Neutralizing sST2 in Limited Cutaneous Systemic Sclerosis by Wagner, A., Köhm, M., Nordin, A., Svenungsson, E., Pfeilschifter, J.M., Radeke, H. H.

“…The pathophysiology of both limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous SSc (dcSSc), representing two subtypes of an autoimmune disease…”
Get full text

Pre-analytical sample handling standardization for reliable measurement of metabolites and lipids in LC-MS-based clinical research by Sens, A., Rischke, S., Hahnefeld, L., Dorochow, E., Schäfer, S.M.G., Thomas, D., Köhm, M., Geisslinger, G., Behrens, F., Gurke, R.

“…[Display omitted] •Analysis of ex vivo distortion in K3ETDA whole blood and plasma.•Establishment of pre-analytical sample-handling protocols for clinical…”
Get full text

Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab by Mojtahed Poor, S., Ulshöfer, T., Gabriel, L. A., Henke, M., Köhm, M., Behrens, F., Geisslinger, G., Parnham, M. J., Burkhardt, H., Schiffmann, S.

“…Summary Introduction of biotherapeutics has been a major milestone in the treatment of different chronic diseases. Nevertheless, the immune system can…”
Get full text

Association analysis of psoriasis vulgaris and psoriatic arthritis with loss-of-function mutations in IL36RN in German patients by Löhr, S., Uebe, S., Behrens, F., Böhm, B., Köhm, M., Traupe, H., Oji, V., Burkhardt, H., Reis, A., Hüffmeier, U.

Get full text

Psoriatic arthritis : Current therapeutic standards by Köhm, M, Behrens, F

“…Psoriatic arthritis (PsA) is a heterogeneous immune-mediated disease that usually involves the skin and joints but can also affect the entheses, spine and…”
Get full text

Frühe, zeitlich begrenzte intensive immunmodulatorische Therapie zum Erreichen einer Remission in Psoriasis Arthritis by Köhm, M.

Get full text

Treatment of psoriatic arthritis : Are there differential indications? by Köhm, M, Behrens, F

“…Psoriatic arthritis (PsA) is a very heterogeneous immune-mediated disease that usually involves skin and joints but can also affect entheses and…”
Get full text

Therapie der Psoriasisarthritis: Gibt es eine Differenzialindikation? by Köhm, M., Behrens, F.

“…Zusammenfassung Die Psoriasisarthritis (PsA) ist eine sehr heterogene Erkrankung, die neben der Beteiligung der Haut und der Gelenke auch enthesiale, axiale…”
Get full text

Pharmacotherapy of psoriatic arthritis. Treatment recommendations against the background of limited evidence by Köhm, M, Behrens, F

“…International treatment recommendations for assisting the choice of pharmaceutical treatment of psoriatic arthritis are currently available in two different…”
Get full text

Treatment of psoriatic arthritis : Are there differential indications? by Köhm, M, Behrens, F

Get full text

Psoriasisarthritis: Aktuelle therapeutische Standards by Köhm, M., Behrens, F.

“…Zusammenfassung Die Psoriasisarthritis (PsA) ist eine heterogene Erkrankung, die neben der Haut und den Gelenken auch eine Beteiligung der Enthesen, der…”
Get full text

Association analysis of psoriasis vulgaris and psoriatic arthritis with loss‐of‐function mutations in IL 36 RN in German patients by Löhr, S., Uebe, S., Behrens, F., Böhm, B., Köhm, M., Traupe, H., Oji, V., Burkhardt, H., Reis, A., Hüffmeier, U.

Get full text

Imaging of psoriatic arthritis and aspects of radiographic progression by Baraliakos, X, Kleyer, A, Simon, D, Köhm, M, Ohrndorf, S, Sewerin, P

“…Psoriatic arthritis (PsA) is a heterogeneous multifactorial disease with musculoskeletal involvement, which can be manifested as monoarthritis, oligoarthritis…”
Get full text

OC 02.1 Dose-Dependent Elimination of HPA-1a Platelets by Subcutaneous RLYB212, a Monoclonal Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia by Geisen, C., Fleck, E., Gastón Schäfer, S., Walter, C., Braeuninger, S., Søndergaard Jensen, J., Armstrong, R., Sheridan, D., Patki, K., Kjaer, M., Behrens, F., Seifried, E., Kjeldsen-Kragh, J., Köhm, M.

Get full text

Increased Serum Levels of the IL ‐33 Neutralizing sST 2 in Limited Cutaneous Systemic Sclerosis by Wagner, A., Köhm, M., Nordin, A., Svenungsson, E., Pfeilschifter, J.M., Radeke, H. H.

“…Abstract The pathophysiology of both limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous SSc (dcSSc), representing two subtypes of an autoimmune…”
Get full text

Pharmakotherapie der Psoriasisarthritis: Behandlungsempfehlungen vor dem Hintergrund limitierter Evidenzen by Köhm, M., Behrens, F.

“…Zusammenfassung Zur Unterstützung bei der Auswahl medikamentöser Behandlungen der Psoriasisarthritis liegen derzeit 2 Versionen von internationalen…”
Get full text

Early, timely limited intensive immune-modulatory treatment for achievement of remission state in psoriatic arthritis by Köhm, M

Get full text

Value of combining biologics with methotrexate for treatment of psoriatic arthritis-questions remain by Dauth, S, Köhm, M, Rossmanith, T, Herrmann, E, Lehn, A, Burkhardt, H, Behrens, F

“…Concomitant methotrexate (MTX) improves the therapeutic effect of biologic therapies in rheumatoid arthritis treatment. However, the influence of MTX on…”
Get full text

Personalisierte Medizin bei Zytokin-gerichteten Therapien by Behrens, F., Köhm, M.

“…Zusammenfassung Personalisierte Medizin versucht über die Definition von Patientencharakteristika (Biomarker) eine Prädiktion von Wirksamkeit und Sicherheit…”
Get full text